Guidance for the Use of Pre-exposure Prophylaxis (PrEP) for the Prevention of HIV Acquisition in British Columbia
These guidelines were developed by the British Columbia Centre for Excellence in HIV/AIDS and focus on the provision of PrEP as a part of a comprehensive approach to combination prevention, drawing on implementation and research evidence and WHO recommendations.
Mapping Implementation Science with Expert Recommendations for Implementing Change (MIS-ERIC): Strategies to Improve PrEP Use among Black Cisgender Women Living in Mississippi
This article from the Journal of Racial and Ethnic Health Disparities describes an analysis of qualitative interviews undertaken in Mississippi, USA with Black, cisgender women at risk for HIV and community healthcare clinic staff who work directly with this population in order to identify barriers to PrEP uptake and select appropriate implementation strategies to increase…
A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia
This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.
Uptake of and Adherence to Oral Pre-exposure Prophylaxis among Adolescent Girls and Young Women at High Risk of HIV-Infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers
This article from BMC Women’s Health describes the results of a qualitative study exploring the experiences, facilitators and barriers of PrEP uptake and adherence to PrEP among adolescent girls and young women in Kampala, Uganda.
Self-reported and Pill Count Measures of Adherence to Oral HIV PrEP among Female Sex Workers Living in South-Western Uganda
This article from PLOS One reports on a study evaluating PrEP adherence amongst female sex workers in southwestern Uganda using clinic-based pill counts and self-reported measures, and examines factors associated with protective levels of adherence.
Initial Implementation of HIV PrEP for People who are Incarcerated in Zambia: A cross-sectional observational study
This article from The Lancet HIV describes a cross-sectional observational study of a PrEP programme implemented between October 2020 and March 2021 in 16 criminal justice facilities in four Zambian provinces.
Prevalence of HIV PrEP Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use
This article from the Journal of the American Medical Association (JAMA) estimates HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use status in the USA.
Results from a Safety Study of the Dapivirine Vaginal Ring and Oral PrEP in Breastfeeding Mother-Infant Pairs
This poster from AIDS 2022 presents results from the MTN-043/B-Protected trial, comparing the safety profile of the dapivirine vaginal ring against oral PrEP use during breastfeeding.
Resources for Providing Oral PrEP in Family Planning Settings
The job aids in this publication were developed to facilitate integration of PrEP into Family Planning (FP) services by giving FP providers practical guidance on PrEP eligibility assessment, key informed choice counselling messages about PrEP, and initiation of PrEP for clients who are eligible and want to use it. These job aids can be branded…
PrEP-Related Stigma and PrEP Use among Gay, Bisexual and Other Men who Have Sex with Men in Ontario and British Columbia, Canada
This article from AIDS Research and Therapy explores the association between PrEP-related stigma and PrEP use amongst gay and bisexual men who have sex with men in Ontario and British Columbia, Canada.
Exploring the Use of Oral PrEP Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial
This article from AIDS and Behavior explores PrEP use and post-trial PrEP access amongst women who had taken part in the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial in Durban, South Africa, and describes barriers to access.